Qiao C, Zhang HX, Tian XT, Zhang YJ, Li DH. Harnessing multi-omics approaches to elucidate the role of Chinese herbal compounds in chemotherapy-induced gastrointestinal damage. World J Gastrointest Oncol 2025; 17(2): 101500 [DOI: 10.4251/wjgo.v17.i2.101500]
Corresponding Author of This Article
De-Hui Li, MD, Doctor, Department of Oncology II, The First Affiliated Hospital of Hebei University of Chinese Medicine (Hebei Province Hospital of Chinese Medicine), Key Laboratory of Integrated Chinese and Western Medicine for Gastroenterology Research, Hebei Industrial Technology Institute for Traditional Chinese Medicine Preparation, No. 389 Zhongshan East Road, Chang’an District, Shijiazhuang 050000, Hebei Province, China. 258289951@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 101500 Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.101500
Harnessing multi-omics approaches to elucidate the role of Chinese herbal compounds in chemotherapy-induced gastrointestinal damage
Chang Qiao, Hao-Xiang Zhang, Xiao-Tong Tian, Yan-Jing Zhang, De-Hui Li
Chang Qiao, Xiao-Tong Tian, Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050000, Hebei Province, China
Hao-Xiang Zhang, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
Yan-Jing Zhang, Department of Oncology I, The First Affiliated Hospital of Hebei University of Chinese Medicine (Hebei Province Hospital of Chinese Medicine), Shijiazhuang 050000, Hebei Province, China
De-Hui Li, Department of Oncology II, The First Affiliated Hospital of Hebei University of Chinese Medicine (Hebei Province Hospital of Chinese Medicine), Key Laboratory of Integrated Chinese and Western Medicine for Gastroenterology Research, Hebei Industrial Technology Institute for Traditional Chinese Medicine Preparation, Shijiazhuang 050000, Hebei Province, China
Co-first authors: Chang Qiao and Hao-Xiang Zhang.
Co-corresponding authors: Yan-Jing Zhang and De-Hui Li.
Author contributions: Qiao C and Zhang HX contributed equally to this work; Li DH and Zhang YJ designed the overall concept and outline of the manuscript; Qiao C and Zhang HX contributed to the writing and editing of the manuscript and a review of the literature; Tian XT organized data. All authors have read and approved the final manuscript.
Supported by 2023 Government-funded Project of the Outstanding Talents Training Program in Clinical Medicine, No. ZF2023165; Key Research and Development Projects of Hebei Province, No. 18277731D; and Natural Science Foundation of Hebei Province, No. H202423105.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: De-Hui Li, MD, Doctor, Department of Oncology II, The First Affiliated Hospital of Hebei University of Chinese Medicine (Hebei Province Hospital of Chinese Medicine), Key Laboratory of Integrated Chinese and Western Medicine for Gastroenterology Research, Hebei Industrial Technology Institute for Traditional Chinese Medicine Preparation, No. 389 Zhongshan East Road, Chang’an District, Shijiazhuang 050000, Hebei Province, China. 258289951@qq.com
Received: September 16, 2024 Revised: November 11, 2024 Accepted: November 25, 2024 Published online: February 15, 2025 Processing time: 123 Days and 15.1 Hours
Abstract
In this editorial, we discuss the findings reported by Wang et al in the latest issue of the World Journal of Gastrointestinal Oncology. Various research methodologies, including microbiome analysis, assert that the Tzu-Chi Cancer-Antagonizing and Life-Protecting II Decoction of Chinese herbal compounds mitigates inflammatory responses by inhibiting the NF-κB signaling pathway. This action helps maintain the dynamic equilibrium of the intestinal microecology and lessens chemotherapy-induced gastrointestinal damage. The efficacy of these compounds is intimately linked to the composition of intestinal microbes. These compounds regulate intestinal microecology by virtue of their specific compatibility and effectiveness, thereby enhancing the overall therapeutic outcomes of cancer chemotherapy. Nonetheless, the exact mechanisms underlying these effects warrant further investigation. Multi-omics technologies offer a systematic approach to elucidate the mechanisms and effectiveness of Chinese herbal compounds in vivo. This manuscript reviews the application of multi-omics technologies to Chinese herbal compounds and explores their potential role in modulating the gastrointestinal microenvironment following cancer chemotherapy, thus providing a theoretical foundation for their continued use in adjunct cancer treatment.
Core Tip: We discussed the mechanism and advantages of Chinese herbal compounds based on metabolomics, transcriptomics, microbiomes, and other multi-omics technologies in regulating the gastrointestinal microenvironment after cancer chemotherapy, providing theoretical support for Chinese herbal compounds to assist cancer chemotherapy.
